| 摘要 |
The specification describes compounds and compositions which are useful in the treatment of amyloidosis. The compounds inhibit amyloid deposition. The therapeutic compounds have at least one anionic group covalently attached to a carrier molecule which is capable of inhibiting an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to inhibit amyloid deposition. In one embodiment, the anionic group covalently attached to the carrier molecule is a sulfonate group. Accordingly, the therapeutic compound can have the formula: Q-[-SO3-X+]n wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer. In another embodiment, the anionic group is a sulfate group. Carrier molecules which can be used include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups heterocyclic groups, aromatic groups and combinations thereof. Preferred therapeutic compounds include poly(vinylsulfonic acid), ethanesulfonic acid, sucrose octasulfate, 1 ,2-ethanediol disulfuric acid, 1,2ethanedisulfonic acid, 1 ,3-propanediol disulfuric acid, 1 ,3-propanedisuifonic acid, 1,4butanediol disulfuric acid, 1,4-butanedisulfonic acid, 1,5-pentanedisulfonic acid, taurine, - (N-morpholino)propallesulfonic acid, tetrahydrothiophenc- 1,1 -dioside-1,4-disulfonic acid, 4 hdroxybutanc-1-suifonic acid, or pharmaceutically acceptable salts.
|
